These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30359047)

  • 21. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
    Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
    Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
    Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC
    Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with buprenorphine versus methadone use in pregnancy.
    Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N
    Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.
    Johnson S; Martin PR
    Am J Drug Alcohol Abuse; 2018; 44(3):310-316. PubMed ID: 28829626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial.
    Stein M; Herman D; Conti M; Anderson B; Bailey G
    Addiction; 2020 Jan; 115(1):82-94. PubMed ID: 31430414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do daily interactive voice response reports of smoking behavior correspond with retrospective reports?
    Toll BA; Cooney NL; McKee SA; O'Malley SS
    Psychol Addict Behav; 2005 Sep; 19(3):291-5. PubMed ID: 16187808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of opioid maintenance treatments when analgesic treatments are required].
    Laprevote V; Geoffroy PA; Rolland B; Leheup BF; Di Patrizio P; Cottencin O; Schwan R
    Presse Med; 2013; 42(7-8):1085-90. PubMed ID: 23518339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.
    Fiellin DA; Barry DT; Sullivan LE; Cutter CJ; Moore BA; O'Connor PG; Schottenfeld RS
    Am J Med; 2013 Jan; 126(1):74.e11-7. PubMed ID: 23260506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
    Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
    Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.